LYEL - Lyell Immunopharma, Inc.
IEX Last Trade
0.6608
0.008 1.165%
Share volume: 9,589
Last Updated: Fri 27 Dec 2024 05:30:42 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$0.65
0.01
1.18%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-02-28 | 2023-05-04 | 2023-08-08 | 2023-11-07 | 2024-02-28 | 2024-05-06 | |
| Total revenue | 35.741 M | 3.000 K | 48.386 M | 65.000 K | 27.000 K | 25.000 K | 13.000 K | 3.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 35.741 M | 3.000 K | 48.386 M | 65.000 K | 27.000 K | 25.000 K | 13.000 K | 3.000 K | |
| -99.99% | 1,612,766.67% | -99.87% | -58.46% | -7.41% | -48.00% | -76.92% | |||
| Operating expenses | 74.173 M | 67.691 M | 64.380 M | 63.909 M | 66.501 M | 59.356 M | 60.162 M | 56.668 M | |
| Selling general and admin | 30.454 M | 26.084 M | 26.348 M | 19.279 M | 19.030 M | 15.507 M | 13.167 M | 13.494 M | |
| Research and development | 43.719 M | 41.607 M | 38.032 M | 44.630 M | 47.471 M | 43.849 M | 46.995 M | 43.174 M | |
| Total expenses | 73.002 M | 66.440 M | 63.170 M | 62.621 M | 66.501 M | 59.356 M | 61.450 M | 56.668 M | |
| -8.99% | -4.92% | -0.87% | 6.20% | -10.74% | 3.53% | -7.78% | |||
| Operating income | -37.261 M | -66.437 M | -14.784 M | -62.556 M | -66.474 M | -59.331 M | -61.437 M | -56.665 M | |
| Ebit | -37.261 M | -66.437 M | -14.784 M | -62.556 M | -66.474 M | -59.039 M | -59.508 M | -55.575 M | |
| Pretax income | -36.323 M | -70.254 M | -8.397 M | -66.959 M | -63.890 M | -50.853 M | -52.930 M | -60.667 M | |
| 93.41% | -88.05% | 697.42% | -4.58% | -20.41% | 4.08% | 14.62% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -36.323 M | -70.254 M | -8.397 M | -66.959 M | -63.890 M | -50.853 M | -52.930 M | -60.667 M | |
| -93.41% | 88.05% | -697.42% | 4.58% | 20.41% | -4.08% | -14.62% | |||
| Net income | -36.323 M | -70.254 M | -8.397 M | -66.959 M | -63.890 M | -50.853 M | -52.930 M | -60.667 M | |
| -93.41% | 88.05% | -697.42% | 4.58% | 20.41% | -4.08% | -14.62% |